Redesigning the designer drug ecstasy: Non-psychoactive MDMA analogues exhibiting Burkitt's lymphoma cytotoxicity

Michael N. Gandy; Matthew McIldowie; Katie Lewis; Agata M. Wasik; Danielle Salomonczyk; Keith Wagg; Zak A. Millar; David Tindiglia; Philippe Huot; Tom Johnston; Sherri Thiele; Blake Nguyen; Nicholas M. Barnes; Jonathan M. Brotchie; Mathew T. Martin-Iverson; Joanne Nash; John Gordon; Matthew J. Piggott

doi:10.1039/c0md00108b

Redesigning the designer drug ecstasy: Non-psychoactive MDMA analogues exhibiting Burkitt's lymphoma cytotoxicity

Michael N. Gandy, Matthew McIldowie, Katie Lewis, Agata M. Wasik, Danielle Salomonczyk, Keith Wagg, Zak A. Millar, David Tindiglia, Philippe Huot, Tom Johnston, Sherri Thiele, Blake Nguyen, Nicholas M. Barnes, Jonathan M. Brotchie, Mathew T. Martin-Iverson, Joanne Nash, John Gordon, Matthew J. Piggott

Research output: Contribution to journal › Article › peer-review

14 Citations (Scopus)

Abstract

Burkitt's lymphoma (BL) is a particularly aggressive cancer that primarily affects African children. Unfortunately, effective and affordable treatment is out of reach of most of the afflicted. The illicit psychoactive drug methylenedioxymethamphetamine (MDMA, 'ecstasy') is cytotoxic to BL cell lines, but its low potency, psychoactivity and neurotoxicity preclude consideration as a therapeutic drug candidate. This paper describes the discovery of novel α-aryl analogues of MDMA that lack psychoactivity and reduce BL cell line viability with significantly more potency than the lead compound. Preliminary in vitro studies also indicate that the compounds are non-toxic to a relevant neuronal cell line.

Original language	English
Pages (from-to)	287-293
Number of pages	7
Journal	MedChemComm
Volume	1
Issue number	4
DOIs	https://doi.org/10.1039/c0md00108b
Publication status	Published - Oct 2010

Access to Document

10.1039/c0md00108b

Cite this

Gandy, M. N., McIldowie, M., Lewis, K., Wasik, A. M., Salomonczyk, D., Wagg, K., Millar, Z. A., Tindiglia, D., Huot, P., Johnston, T., Thiele, S., Nguyen, B., Barnes, N. M., Brotchie, J. M., Martin-Iverson, M. T., Nash, J., Gordon, J., & Piggott, M. J. (2010). Redesigning the designer drug ecstasy: Non-psychoactive MDMA analogues exhibiting Burkitt's lymphoma cytotoxicity. MedChemComm, 1(4), 287-293. https://doi.org/10.1039/c0md00108b

@article{b5252ea2a30f492da9e07285a990fa3a,

title = "Redesigning the designer drug ecstasy: Non-psychoactive MDMA analogues exhibiting Burkitt's lymphoma cytotoxicity",

abstract = "Burkitt's lymphoma (BL) is a particularly aggressive cancer that primarily affects African children. Unfortunately, effective and affordable treatment is out of reach of most of the afflicted. The illicit psychoactive drug methylenedioxymethamphetamine (MDMA, 'ecstasy') is cytotoxic to BL cell lines, but its low potency, psychoactivity and neurotoxicity preclude consideration as a therapeutic drug candidate. This paper describes the discovery of novel α-aryl analogues of MDMA that lack psychoactivity and reduce BL cell line viability with significantly more potency than the lead compound. Preliminary in vitro studies also indicate that the compounds are non-toxic to a relevant neuronal cell line.",

author = "Gandy, {Michael N.} and Matthew McIldowie and Katie Lewis and Wasik, {Agata M.} and Danielle Salomonczyk and Keith Wagg and Millar, {Zak A.} and David Tindiglia and Philippe Huot and Tom Johnston and Sherri Thiele and Blake Nguyen and Barnes, {Nicholas M.} and Brotchie, {Jonathan M.} and Martin-Iverson, {Mathew T.} and Joanne Nash and John Gordon and Piggott, {Matthew J.}",

year = "2010",

month = oct,

doi = "10.1039/c0md00108b",

language = "English",

volume = "1",

pages = "287--293",

journal = "MedChemComm",

issn = "2040-2503",

publisher = "Royal Society of Chemistry",

number = "4",

}

Gandy, MN, McIldowie, M, Lewis, K, Wasik, AM, Salomonczyk, D, Wagg, K, Millar, ZA, Tindiglia, D, Huot, P, Johnston, T, Thiele, S, Nguyen, B, Barnes, NM, Brotchie, JM, Martin-Iverson, MT, Nash, J, Gordon, J & Piggott, MJ 2010, 'Redesigning the designer drug ecstasy: Non-psychoactive MDMA analogues exhibiting Burkitt's lymphoma cytotoxicity', MedChemComm, vol. 1, no. 4, pp. 287-293. https://doi.org/10.1039/c0md00108b

TY - JOUR

T1 - Redesigning the designer drug ecstasy

T2 - Non-psychoactive MDMA analogues exhibiting Burkitt's lymphoma cytotoxicity

AU - Gandy, Michael N.

AU - McIldowie, Matthew

AU - Lewis, Katie

AU - Wasik, Agata M.

AU - Salomonczyk, Danielle

AU - Wagg, Keith

AU - Millar, Zak A.

AU - Tindiglia, David

AU - Huot, Philippe

AU - Johnston, Tom

AU - Thiele, Sherri

AU - Nguyen, Blake

AU - Barnes, Nicholas M.

AU - Brotchie, Jonathan M.

AU - Martin-Iverson, Mathew T.

AU - Nash, Joanne

AU - Gordon, John

AU - Piggott, Matthew J.

PY - 2010/10

Y1 - 2010/10

N2 - Burkitt's lymphoma (BL) is a particularly aggressive cancer that primarily affects African children. Unfortunately, effective and affordable treatment is out of reach of most of the afflicted. The illicit psychoactive drug methylenedioxymethamphetamine (MDMA, 'ecstasy') is cytotoxic to BL cell lines, but its low potency, psychoactivity and neurotoxicity preclude consideration as a therapeutic drug candidate. This paper describes the discovery of novel α-aryl analogues of MDMA that lack psychoactivity and reduce BL cell line viability with significantly more potency than the lead compound. Preliminary in vitro studies also indicate that the compounds are non-toxic to a relevant neuronal cell line.

AB - Burkitt's lymphoma (BL) is a particularly aggressive cancer that primarily affects African children. Unfortunately, effective and affordable treatment is out of reach of most of the afflicted. The illicit psychoactive drug methylenedioxymethamphetamine (MDMA, 'ecstasy') is cytotoxic to BL cell lines, but its low potency, psychoactivity and neurotoxicity preclude consideration as a therapeutic drug candidate. This paper describes the discovery of novel α-aryl analogues of MDMA that lack psychoactivity and reduce BL cell line viability with significantly more potency than the lead compound. Preliminary in vitro studies also indicate that the compounds are non-toxic to a relevant neuronal cell line.

UR - http://www.scopus.com/inward/record.url?scp=79952527355&partnerID=8YFLogxK

U2 - 10.1039/c0md00108b

DO - 10.1039/c0md00108b

M3 - Article

SN - 2040-2503

VL - 1

SP - 287

EP - 293

JO - MedChemComm

JF - MedChemComm

IS - 4

ER -

Redesigning the designer drug ecstasy: Non-psychoactive MDMA analogues exhibiting Burkitt's lymphoma cytotoxicity

Abstract

Access to Document

Other files and links

Fingerprint

Cite this